Cedars-Sinai Medical Tipsheet for Dec. 2013

Following is a tipsheet of story ideas from Cedars-Sinai Medical Center. To arrange interviews, please contact the individual listed.

Released: 12/13/2013 2:20 PM EST
Source Newsroom: Cedars-Sinai Medical Center
Contact Information

Available for logged-in reporters only

Scientists Design and Test New Approach for Corneal Stem Cell Treatments
Researchers in the Cedars-Sinai Regenerative Medicine Institute have designed and tested a novel, minute-long procedure to prepare human amniotic membrane for use as a scaffold for specialized stem cells that may be used to treat some corneal diseases. This membrane serves as a foundation that supports the growth of stem cells in order to graft them onto the cornea. This new method, explained in a paper published in the journal PLOS ONE, may accelerate research and clinical applications for stem cell corneal transplantation.
CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org; Twitter @CedarsSinaiCara

Cancer Science Evolves, One Consent Form at a Time
Tucked away in freezers chilled to minus 80 degrees Celsius are blood and tissue samples from Cedars-Sinai patients. The freezers that hold these samples also contain the hopes of investigators determined to uncover new treatments for cancer patients across the globe. As cancer research continues to evolve, scientists rely on specimen samples, such as tissue, blood or urine, from generous patients to advance discoveries and personalize care. Biobanks, like the state-of-the-art biobank at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, allow patients to make invaluable contributions to medical research and treatment advances that may ultimately be the solution to their own diagnosis or disease down the road.
CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org; Twitter @CedarsSinaiCara

Cedars-Sinai, UCLA Health System and Select Medical Announce Partnership to Open Medical Rehabilitation Hospital
Cedars-Sinai, UCLA Health System and Select Medical announced today a partnership to create a 138-bed acute inpatient rehabilitation hospital located in the former Century City Hospital. With an expected opening in late 2015, the rehabilitation hospital will serve the growing needs in the community for inpatient rehabilitation, and is also expected to serve as a center for treating complex rehabilitation cases from throughout the nation. The joint venture is an LLC partnership among Cedars-Sinai, UCLA Health System and Select Medical. The vision of the partnership is to develop a world-class regional rehabilitation center providing highly specialized care, advanced treatment, and leading-edge technologies to treat individuals with spinal cord injuries, brain injuries, stroke, amputation, neurological disorders, and musculoskeletal and orthopedic conditions.
CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Cedars-Sinai Receives Fourth Straight Magnet® Recognition for Nursing Excellence from American Nurses Credentialing Center
For the fourth time in a row, the American Nurses Credentialing Center has granted Cedars-Sinai the Magnet® recognition, the most prestigious designation a healthcare organization can receive for excellence in nursing and patient outcomes. Cedars-Sinai in 2000 became the first Southern California hospital to earn the Magnet honor; it is the only hospital in the state to be granted the designation four times. Cedars-Sinai joins a select list of only 12 hospitals worldwide that have earned Magnet recognition four times.
CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Ovarian Cancer Discovery Deepens Knowledge of Survival Outcomes
Researchers in the Women’s Cancer Program at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes. The research found that the 10-gene biomarker panel may identify the aggressiveness of a patient’s disease, help predict survival outcomes and result in novel therapeutic strategies tailored to patients with the most adverse survival outcomes.
CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org; Twitter @CedarsSinaiCara

# # #


Comment/Share